Peptides for Belly Fat: How GH Secretagogues Target Visceral Fat

Why Belly Fat Is Different

Not all body fat is the same, and the fat around your midsection isn't just a cosmetic frustration. It's a different kind of tissue altogether. Subcutaneous fat, the stuff you can pinch under your skin, is relatively harmless from a metabolic standpoint. Visceral fat, the fat packed around your abdominal organs, is an entirely different problem.

• •Metabolically active: Visceral fat functions as an endocrine organ, secreting inflammatory cytokines (IL-6, TNF-alpha) and hormones that disrupt metabolic function
• •Insulin resistance driver: Excess visceral fat is one of the strongest predictors of insulin resistance and type 2 diabetes risk
• •Cardiovascular risk: Visceral fat is independently associated with increased risk of heart disease, stroke, and metabolic syndrome
• •Hormone disruption: Visceral fat produces aromatase, an enzyme that converts testosterone to estrogen, creating a hormonal feedback loop that promotes further fat accumulation
• •Growth hormone responsive: Critically, visceral fat has a high density of growth hormone receptors, making it particularly responsive to GH-mediated lipolysis

Growth Hormone Secretagogues Explained

Growth hormone secretagogues (GHS) are peptides that tell your pituitary gland to produce and release more growth hormone. The important difference from direct HGH injections: secretagogues work with your body's own production machinery, preserving the natural pulsatile release pattern that matters for both safety and effectiveness.[5]

Why does that matter? Because growth hormone works best, and is safest, when it's released in natural pulses rather than held at an artificially elevated level. Secretagogues amplify those pulses. They don't create the flat, supraphysiological GH levels that come with injecting HGH directly.

The three most commonly used GH secretagogues for body composition optimization are Ipamorelin, CJC-1295, and Tesamorelin. Each has distinct properties that make it suitable for different patient profiles and treatment goals.

Ipamorelin for Body Composition

Ipamorelin is a selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol, prolactin, or other hormones. This selectivity makes it one of the cleanest GH secretagogues available.[4]

• •Selective GH release: Ipamorelin activates the ghrelin/GHS receptor to stimulate pituitary GH secretion without raising cortisol or prolactin levels
• •Dose-dependent response: GH release is proportional to dose, allowing physicians to titrate for optimal results
• •Favorable safety profile: Well-tolerated with minimal side effects in clinical studies
• •Synergistic with CJC-1295: Often paired with CJC-1295 to extend the duration and amplitude of GH pulses

CJC-1295: Extended GH Release

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog with a drug affinity complex (DAC) that extends its half-life, allowing for sustained GH elevation over several days from a single injection.

• •Extended half-life: The DAC modification extends CJC-1295's half-life to approximately 6–8 days, compared to minutes for natural GHRH
• •Sustained GH elevation: Produces a steady increase in baseline GH and IGF-1 levels, supporting continuous fat metabolism
• •GHRH pathway activation: Works through the GHRH receptor, complementing the ghrelin receptor pathway used by Ipamorelin
• •Combined protocol advantage: When paired with Ipamorelin, CJC-1295 creates both elevated baseline GH and amplified GH pulses

Tesamorelin: FDA-Approved for Visceral Fat

Tesamorelin is the only GH secretagogue with FDA approval specifically for reducing abdominal fat. Approved in 2010 under the brand name Egrifta, tesamorelin is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.[2]

• •FDA-approved: The only GH-related peptide with FDA approval for abdominal fat reduction
• •Clinically proven: Phase 3 trials demonstrated significant reduction in visceral adipose tissue (VAT) measured by CT scan
• •Liver health benefits: Research shows tesamorelin may reduce liver fat and improve markers of non-alcoholic fatty liver disease
• •Off-label use: Physicians may prescribe tesamorelin off-label for body composition optimization in non-HIV patients

A study by Stanley et al. in The Lancet HIV demonstrated that tesamorelin not only reduced visceral fat but also improved markers of liver health, suggesting metabolic benefits beyond fat reduction alone.[6]

How Growth Hormone Reduces Belly Fat

Growth hormone promotes fat loss through several interconnected mechanisms:

• •Direct lipolysis: GH activates hormone-sensitive lipase in adipocytes, breaking down stored triglycerides into free fatty acids for energy use
• •Increased fatty acid oxidation: GH shifts metabolism toward fat as a fuel source, sparing glucose and amino acids
• •Insulin sensitivity improvement: By reducing visceral fat, GH indirectly improves insulin sensitivity, breaking the cycle of insulin resistance and fat accumulation
• •Preferential visceral fat targeting: Visceral adipocytes express more GH receptors than subcutaneous fat cells, making visceral fat more responsive to GH-mediated lipolysis
• •Lean mass preservation: GH supports protein synthesis and muscle retention during caloric deficit, preventing the muscle loss that often accompanies dieting

Johannsson et al. demonstrated that GH treatment in abdominally obese men produced significant reductions in visceral fat mass while simultaneously improving glucose metabolism and lipid profiles, outcomes that diet and exercise alone often struggle to achieve in this population.[1]

For patients interested in maximizing lean mass alongside fat reduction, our guide on peptides for muscle growth explores how these same GH secretagogues support muscle development. Sleep optimization is also critical for GH function: explore our guide on peptides for sleep.

Clinical Evidence

Treatment Protocols

Body composition protocols at Strong Health are individualized based on patient goals, baseline hormonal levels, and health status:

• •Full assessment: Body composition analysis (DEXA or bioimpedance), hormonal panel (GH, IGF-1, insulin, thyroid, testosterone), metabolic markers
• •Protocol selection: Physician determines the most appropriate peptide(s) based on individual profile. Common protocols include Ipamorelin/CJC-1295 combination or tesamorelin monotherapy
• •Nutrition optimization: Peptide therapy is combined with evidence-based nutrition guidance. Peptides work best in the context of adequate protein intake and moderate caloric deficit
• •Exercise integration: Structured resistance training amplifies the body composition benefits of GH secretagogues
• •Monitoring: Regular labs (IGF-1, insulin, glucose, lipids) and body composition assessments to track progress and adjust protocols
• •Treatment duration: Typical protocols run 3–6 months, with reassessment to determine if continued treatment is warranted

Safety and Side Effects

GH secretagogues have favorable safety profiles compared to direct HGH administration, largely because they maintain natural GH pulsatility. Common side effects include:

• •Water retention: Mild fluid retention is common in the first 2–4 weeks, usually self-resolving
• •Joint stiffness: Temporary joint discomfort or stiffness, particularly in the hands, is occasionally reported
• •Increased hunger: Ipamorelin's activation of the ghrelin receptor may increase appetite initially
• •Injection site reactions: Mild redness or discomfort at the injection site
• •Tingling/numbness: Carpal tunnel-like symptoms have been reported, usually with higher doses and resolving with dose adjustment

Patients with active cancer, diabetic retinopathy, or uncontrolled diabetes should not use GH secretagogues without careful evaluation. Growth hormone can stimulate cell proliferation, which is a concern in the presence of existing malignancies. All protocols require physician oversight and regular monitoring. For a full overview of healing peptides, visit our peptides for healing hub.